| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H29N |
| Molar mass | 319.492 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Igmesine (JO-1,784) is asigma receptoragonist (IC50 = 39 nM (rat brain)).[1][2] It hasneuroprotective andantidepressant-like effects in animal studies,[3][4] as well asnootropic effects in models of age-related cognitive decline.[5] In twophase IIclinical trials, igmesine was found to be effective in the treatment ofdepression and was as active as the comparatorfluoxetine.[2] However, in a largephase III clinical trial, igmesine failed to show significant effectiveness for depression.[6] The drug has not been developed further.[7]